MIAMI--(BUSINESS WIRE)--Nicofi™ announced the launch of a revolutionary patented, fast-acting dissolvable nicotine tablet intended for use as an alternative to smoking. Nicofi is a small sublingual tablet made from pure nicotine and other high-quality ingredients that allows smokers to quickly enjoy nicotine in any situation, especially when they are unable to smoke a cigarette or e-cigarette. This will be welcomed news to the estimated 42 million Americans who do smoke.
Nicofi, which is made in the U.S.A., uses the finest pharmaceutical-grade materials and includes only eight ingredients. There is no tar, tobacco, formaldehyde or any harmful ingredients. By comparison, cigarettes contain approximately 600 ingredients and, when burned, create more than 7,000 chemicals, 69 of which are known to cause cancer, according to the American Lung Association.†
Available in packs of 20 tablets, Nicofi is meant for adults who are looking to substitute the use of cigarettes and e-cigarettes. It is recommended to take one tablet at a time without exceeding 20 tablets, per day.
With its breakthrough, patented IntraTab™ Drug Delivery Technology, Nicofi was studied in controlled trials and clinically proven* to deliver nicotine quickly, similar to smoking a cigarette, but without the harmful dangers of tar, tobacco, carcinogens, vapors or odors found in cigarettes or e-cigarettes. Nicofi’s proprietary speed of action is two to three times faster than nicotine gum and lozenges.* This gives smokers permission to enjoy nicotine quickly and conveniently in places where they are prohibited from smoking and vaping like airplanes, trains, museums, public buildings, offices, schools, hotels, bars, restaurants, stadiums, arenas, and other locations or situations.
How Nicofi Works:
Nicofi is a sublingual tablet, which gets placed under the bottom of the tongue and dissolves without chewing or swallowing, to deliver a strong, fast rush of nicotine. The IntraTab Drug Delivery Technology allows Nicofi to disintegrate and release a solution of nicotine directly into the bloodstream through the lining of the mouth. Nicofi works about as quickly as smoking a cigarette or e-cigarette, unlike nicotine polacrilex gum or lozenges, which take longer to deliver nicotine.* One Nicofi tablet is equivalent to the approximate amount of nicotine received from one cigarette.
Nicofi is now available at select retailers and on www.nicofi.com.
For additional information about Nicofi, visit www.nicofi.com.
About Ross Myles Health, LLC
Ross Myles Health is a specialty pharmaceutical company focused on the development and commercialization of novel pharmaceutical and consumer health care products, which address significant unmet consumer needs. Ross Myles currently has five products under review by the FDA and more than 10 products in clinical and preclinical development programs. Based in Miami, Florida Ross Myles is the sister company of PL Developments, a leading manufacturer of store brand consumer health care products that is head quartered in Westbury, NY with additional manufacturing facilities in South Carolina and California.
Warning: Nicofi is intended for use by persons of legal smoking age, not by non-smokers or by children, women who are pregnant or breastfeeding, or persons with or at risk of heart disease, high blood pressure, diabetes, or taking medicine for depression or asthma. Nicotine is highly addictive and habit forming, and can be lethal if ingested by a child, a pet or even misused by an adult. Please enjoy Nicofi responsibly and only take as directed. Nicofi is not a treatment for nicotine addiction or an aid for smoking cessation. If you smoke tobacco products, you are encouraged to stop. Go to www.smokefree.gov for information and resources to help you quit.
*Based on open-label, single-dose pharmacokinetic evaluation of NicofiTM 1mg sublingual tablets in healthy smokers under fasted conditions, as demonstrated by similar blood PK parameters (tmax, Cmax, AUC), compared to nicotine polacrilex gum and lozenges as reported in the scientific literature: Pharmacokinetics of Nicotine Polacrilex Gum, Nicotine & Tobacco Research, Volume 5, Number 5 (October 2003) 635-644.
†American Lung Association. What’s In a Cigarette? Retrieved from http://www.lung.org/stop-smoking/about-smoking/facts-figures/whats-in-a-cigarette.
